



MEDIA RELEASE – 17 AUGUST, 2016

FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2016

1. Summary

A\$M	FY2016	Increase on previous year
Revenue	5,052	20%
Underlying EBITDA (before non-recurring items)	876	20%
EBITDA (after non-recurring items)	880	27%
Net Profit (after non-recurring items)	451	30%
Cash generated from operations	708	38%
Earnings per share (after non-recurring items) (A\$)	1.09	27%

- FY2016 guidance achieved (Constant Currency Underlying EBITDA A\$831 v A\$815-840 million)
- Revenue growth 20% to A\$5.1 billion
- Earnings per share growth 27% to A\$1.09
- Final dividend up 7.3% to A\$0.44 per share (full-year up 5.7% to A\$0.74 per share), 30% franked, payable on 27 September 2016, Dividend Reinvestment Plan suspended
- Strong earnings growth in Europe and the USA
- Accretive acquisitions successfully integrated
- Ongoing EBITDA growth expected in FY2017

2. Commentary on Results

Sonic Healthcare today reported a net profit for the year to 30 June 2016 of A\$451 million, on revenues of A\$5,052 million.

Sonic's CEO, Dr Colin Goldschmidt, said: "2016 was a banner year for Sonic Healthcare, breaking through the dual milestones of A\$5 billion in annual revenues and A\$1 in earnings per share. These results were achieved in FY '16, despite some headwinds in our Australian businesses. The benefits of our diversified international expansion were very obvious in this year's results, with both our European and US businesses showing significant earnings growth. The Australian headwinds now appear to be abating.

The acquisitions we completed early in the year, Medisupport in Switzerland and KLD in Belgium, have both delivered as expected and have been smoothly integrated into the Sonic group – a credit to the local management teams - with further synergies to be realised in 2017. Our UK joint venture, Health Services Laboratories, continues to exceed expectations and is well positioned to gain further NHS outsourcing contracts. Sonic's strategy to lead the consolidation of fragmented laboratory markets continues, with a number of synergistic acquisition and contract opportunities in our pipeline."

Dr Goldschmidt added: "Over the last five years, we have invested heavily in new, state-of-the-art laboratories around the world, green field imaging practices, and in equipment platforms and automation systems, creating ultra-modern facilities with the capacity for ongoing growth and efficiency capture. Although this investment phase is now slowing, we continue to invest in information technology, and in our people, to ensure that our services and quality remain consistently at cutting-edge levels, for the benefit of our referring clinicians and the tens of millions of patients we serve each year.

I wish to thank the entire global Sonic team, now more than 31,000 strong, for their ongoing dedication and expertise to improve Sonic and the healthcare systems in which we operate."

Dr Colin Goldschmidt
CEO
Sonic Healthcare Limited
Ph.: (02) 9855 5333
Fax: (02) 9878 5066

For further information regarding the result, please refer to Dr Goldschmidt's PowerPoint Presentation and to Sonic's Appendix 4E Preliminary Final Report, both of which will be posted on the Sonic Healthcare website by 10.00am, 17 August 2016 (www.sonichealthcare.com).

Forward-looking statements

This media release may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts and unexpected growth in costs and expenses. The statements being made in this media release do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Sonic Healthcare). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements.